Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24-10-2019
AVNphotolab / iStockphoto.com
A Brazilian federal judge has granted a preliminary injunction against a patent for US-based Gilead’s Sovaldi (sofosbuvir) drug, used to treat hepatitis C, following a complaint by a presidential candidate.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
INPI, patent, preliminary injunction, Gilead, hepatitis C, Gabriel Di Blasi, Di Blasi Parente & Associados, Marina Silva, Eduardo Jorge, Sovaldi
